Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021

- Nearly half of people with migraine hesitated to seek care, choosing self-management and out of concern their disease would not be taken seriously, based on new findings from OVERCOME (U.S.), the largest population-based study of its kind - Emgality® (galcanezumab-gnlm) achieved greater adherence